The global dry eye market is expected to reach $7.78b by 2025 (Transparency Market Research). The dry eye market includes pharmaceuticals, diagnostics, surgery and new devices (profiled below). Key drivers include: the aging population; the rising prevalence of diseases like diabetes and rheumatoid arthritis that can give rise to dry eyes; greater awareness of eye health; and new technologies that …
The Trump Administration Is Proposing Changes to Medicare Pay For Accountable Care Organization (ACO) Models
Medicare ACOs began in 2012 and have enrolled more than 10 million beneficiaries so far. If they provide care for less than certain cost targets — while meeting quality of care standards — then they get to share in any of the savings. Commercial insurers and Medicaid have also adopted ACOs in the past decade. About 82% of the 561 …
New Signs of Disrupting Healthcare Delivery. Like Apple, Amazon Is Opening Healthcare Clinics
The retail giant plans to start a Seattle-based clinic, which will serve a small group of employees at first. The program will then be expanded in early 2019, as part of an ongoing quest to reduce health care costs and cut red tape. Apple also started clinics, initially to serve Apple’s employees in Santa Clara County. Recently, Amazon teamed up …
Emergent BioSolutions Is Buying PaxVax For $270m
Emergent BioSolutions, Inc., a $560.8m specialty pharmaceutical company focused on public health threats, is buying PaxVax, Inc., a PE- backed company focuses on specialty vaccines against existing and emerging infectious diseases. The deal expands Emergent’s specialty vaccine platform. PaxVax’s main product include Vivotif, the only oral vaccine licensed by FDA to prevent typhoid fever, and Vaxhora, a vaccine against cholera developed for the …
The Impact of Trump’s Tariffs
President Trump’s tariffs on Chinese imports could cost American medical device makers more than $1.5b annually, according to some estimates. MRIs, CT scanners, pacemakers, sonograms and other imaging components were all included in the list of items subject to the 25% tariffs that went into effect on June 6. Also included are a variety of medical supplies and instruments made …
Celgene Acquires Juno Therapeutics For $9b
Celgene Corp., a $12.5b developer of therapies for cancer and inflammatory diseases is buying Juno Therapeutics Inc., a Seattle-based biotech company making cutting-edge cancer immunotherapy treatments. The Deal expands Celgene’s portfolio of blood-cancer drugs. Juno is one of leaders in a new kind of cancer treatment, known as CAR-T, that takes a patient’s own immune cells, modifies them and then sets them …
Sweeping New EU Regulations, Taking Effect in 2020, Will Create Upheavals in The European Medtech and IVD Markets
Starting in 2020 medtech firms will be competing in a significantly more complicated European market. New Medical Devices Regulations (MDR) were written to strengthen device safety standards but they will make it far more onerous and expensive for medtech firms to market their products in Europe. Because of the MDR, many smaller companies may not be able to comply, and …
Novartis, Abbott, GE, Siemens, and Other Healthcare Giants Are Reversing Previous Diversification Strategies
Novartis/Alcon After assessing strategic options for Alcon, Novartis is spin-ning it out to shareholders. As a result, both companies will now rivet on their core strengths –pharmaceuticals and oph-thalmic devices, respectively. When Novartis acquired Alcon in 2011 for $52b, the business included surgical, vision care and ophthalmic pharmaceuticals. In 2016, Novartis absorbed Alcon’s drug business, leaving Alcon as pure …
Sivantos and Widex Announce Merger
Sivantos, a Germany-based hearing aid maker previously owned by Siemens will merge with Widex, a Denmark-based hearing aid maker to form a company with an enterprise value of more than $8b. Sivantos, owned by EQT Partners, and Widex are merging to form the 3rd largest hearing aid maker. The merger will likely push back EQT’s plans for an IPO of Sivantos by a few years, …
As part of J&J’s de-diversifying, it is selling its Advanced Sterilization Products (ASP) business to Fortive Corportion (a Danaher spinout)
Fortive Corporation, a $6.86b diversified conglomerate spinout from Danaher, is acquiring Johnson & Johnson’s Advanced Sterilization Products (ASP) business for $2.8b. ASP provides sterilization and disinfection systems and low-temperature hydrogen peroxide sterilization technology. ASP’s products include the STERRAD system for sterilizing instruments, EVOTECH and ENDOCLENS systems for endoscope reprocessing and cleaning. JNJ sold approximately $2.1b of both units. Last year, JNJ acquired Actelion for …